PDCD1 and neoplasm: For instance, PD-L1 is enriched on breast cancer cell-derived EVs, where it binds to PD-1 on T cells, suppressing their activation and cytotoxic function, thereby dampening anti-tumor immunity within the tumor microenvironment [56].